Agios Pharma (AGIO) Reiterated at Overweight by Cantor Fitzgerald as PDUFA Date Approaches

October 15, 2026 7:28 AM

Cantor Fitzgerald analyst Eric Schmidt reiterated an Overweight rating on Agios Pharma (NASDAQ: AGIO).The analyst commented, "The drug's PDUFA date ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found